Abstract
The remarkable results achieved with antibodies directed against immune checkpoints for the treatment of some solid tumors has highlighted the importance of understanding the biology and mechanisms of cellular interactions within the tumor microenvironment (TME). A majority of antibodies in development for treating cancer are directed against immune checkpoints (ICs). They are being evaluated in more than 3000 clinical trials as first or second lines of treatment, alone or in combination with other antibodies and reagents for the treatment of about 50 types of cancer. The percentage of antibody-drug conjugates (ADCs) has also significantly increased within the last decade. Major improvements have been made in linker chemistry and payload efficacy. A large number of bispecific antibodies and chimeric antigen receptor T cells (CAR-Ts) are also now being clinically evaluated, and personalized tumor vaccines could play an increasingly important role. Future cancer therapy involving antibodies will most likely comprise a combination of different approaches devised according to our knowledge of the tumor’s immunobiology and its interaction with the tumor microenvironment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Selected Literature
Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1):e000911. https://doi.org/10.1136/jitc-2020-000911.
Bausch-Fluck D, Goldmann U, Müller S, et al. The in silico human surfaceome. Proc Natl Acad Sci U S A. 2018;115(46):E10988–97. https://doi.org/10.1073/pnas.1808790115.
Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76(7):1683–9. https://doi.org/10.1158/0008-5472.CAN-15-2125.
Crowther MD, Dolton G, Legut M, et al. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1 [published correction appears in Nat Immunol. 2020 Mar 2]. Nat Immunol. 2020;21(2):178–85. https://doi.org/10.1038/s41590-019-0578-8.
Danielli R, Patuzzo R, Di Giacomo AM, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015;64(8):999–1009. https://doi.org/10.1007/s00262-015-1704-6.
Finck A, Gill SI, June CH. Cancer immunotherapy comes of age and looks for maturity. Nat Commun. 2020;11(1):3325. https://doi.org/10.1038/s41467-020-17140-5.
García-Muñoz R, Anton-Remirez J, Nájera MJ, et al. GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race. Future Sci OA. 2019;5(3):FSO375. https://doi.org/10.4155/fsoa-2018-0122. Published 2020 Jul 3.
Jung H, Kim HS, Kim JY, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10(1):4278. https://doi.org/10.1038/s41467-019-12159-9. Published 2019 Sep 19.
Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs. 2020;12(1):1703531. https://doi.org/10.1080/19420862.2019.1703531.
Klar AS, Gopinadh J, Kleber S, et al. Treatment with 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and facilitates cytotoxic T lymphocyte-mediated tumor cell killing. PLoS One. 2015;10(10):e0139221. https://doi.org/10.1371/journal.pone.0139221.
Leung D, Wurst JM, Liu T, et al. Antibody conjugates—recent advances and future innovations. Antibodies. 2020;9(1):2. https://doi.org/10.3390/antib9010002.
Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–19. https://doi.org/10.1038/s41422-020-0337-2.
Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Epigenetic mechanisms of resistance to immune checkpoint inhibitors. Biomol Ther. 2020;10(7):1061. https://doi.org/10.3390/biom10071061.
Pietersz GA, Wang X, Yap ML, Lim B, Peter K. Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies. Nanomedicine. 2017;12(15):1873–89. https://doi.org/10.2217/nnm-2017-0043.
Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668–74. https://doi.org/10.1200/JCO.2017.75.6270.
Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6. https://doi.org/10.1038/nature23003.
Scaranti M, Cojocaru E, Banerjee S, et al. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 2020;17:349–59. https://doi.org/10.1038/s41571-020-0339-5.
Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. https://doi.org/10.1126/science.aba7365.
Villanueva L, Álvarez-Errico D, Esteller M. The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 2020;41(8):676–91. https://doi.org/10.1016/j.it.2020.06.002.
Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529–37. https://doi.org/10.1200/JCO.2017.73.3402.
Xin Yu J, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global. Nat Rev Drug Discov. 2019;18(12):899–900. https://doi.org/10.1038/d41573-019-00167-9.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Little, M. (2021). Outlook. In: Antibodies for Treating Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-72599-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-72599-0_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-72598-3
Online ISBN: 978-3-030-72599-0
eBook Packages: MedicineMedicine (R0)